Why the study?
Although recombinant human thrombopoietin improves platelet counts in chronic liver disease-associated thrombocytopenia, whether concomitant infections influence its efficacy remains unclear.
Does concomitant infection influence the efficacy of recombinant human thrombopoietin in patients with chronic liver disease-associated thrombocytopenia?
Population
259 patients with chronic liver disease-associated thrombocytopenia who received rhTPO
Comparison
Concomitant infection vs non-concomitant infection
Design
Retrospective propensity score-matched study
Authors
Loading...
rhTPO efficacy appears comparable with or without infections in CLD thrombocytopenia; supports consideration but leaves open need for prospective trials.
Does concomitant infection influence the efficacy of recombinant human thrombopoietin in patients with chronic liver disease-associated thrombocytopenia?
Recombinant human thrombopoietin effectively improves platelet counts in chronic liver disease-associated thrombocytopenia, with comparable efficacy regardless of concomitant infection status.
Wei et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: